Core Viewpoint - The Hong Kong stock market experienced a slight decline on August 21, while the innovative drug sector showed resilience, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising by 1.12% after two consecutive days of decline, indicating a potential recovery in this sector [1]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) had a trading volume of 389 million yuan, ending the day with a price increase of 1.12% [1]. - The index tracked by the ETF has a price-to-sales ratio of 3.59, which is significantly lower than that of U.S. biotech indices, suggesting attractive valuation levels [5]. - The index has shown a cumulative increase of 101.58% year-to-date as of July 31, outperforming other indices such as the Hang Seng Index and the Hang Seng Tech Index by 78.08% and 79.53% respectively [9]. Group 2: Industry Trends - The innovative drug sector is experiencing increased volatility, primarily due to previous gains and short-term market divergences, but long-term factors are contributing to a high level of certainty in this sector [3]. - The Chinese government has established a comprehensive policy framework to support the innovative drug industry, emphasizing the creation of a globally competitive innovation ecosystem [3]. - In the first half of 2025, the National Medical Products Administration approved 43 innovative drugs, marking a 59% increase year-on-year, nearing the total of 48 approvals for the entire year of 2024 [4]. Group 3: Company Performance - Leading innovative drug companies, such as BeiGene, have reported a turnaround in profitability, indicating a shift from a focus on research and development to realizing value [3]. - The innovative drug sector is expected to benefit from increased external licensing transactions, with the total licensing amount exceeding $60.8 billion in the first half of 2025, indicating a strong growth trajectory [3]. - The innovative drug industry is entering a new phase characterized by qualitative improvements, with major firms expected to continue delivering strong earnings and growth [7].

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.24% to close at 25,104.61 points, and a total trading volume of HKD 239.49 billion [1] - The Hang Seng Tech Index was the worst performer, dropping 0.77% to 5,498.5 points [1] - Huatai Securities noted that the market is in a critical phase with a lack of trading themes and awaiting verification of significant domestic and overseas events, suggesting a window for position adjustment [1] Blue-Chip Stocks Performance - China Resources Power (00836) led the blue-chip decline, falling 5.9% to HKD 18.51, contributing a loss of 3.86 points to the Hang Seng Index [2] - The company reported a revenue of HKD 50.267 billion for the first half of 2025, a decrease of 1.67% year-on-year, and a profit attributable to shareholders of HKD 7.872 billion, down 15.92% [2] - Other notable blue-chip movements included China Biologic Products (01177) rising 3.49% and China Unicom (00762) increasing by 3.39% [2] Sector Highlights High-Speed Rail Infrastructure - Major technology stocks generally weakened, while high-speed rail infrastructure stocks performed well, with China CNR (01766) rising 5.85% and Times Electric (03898) increasing by 5.43% [3] - The National Railway Group announced a tender for 210 high-speed train sets, exceeding market expectations, indicating a positive outlook for the sector [3] Pharmaceutical Sector - The pharmaceutical sector saw most stocks rise, with Basilea Pharmaceutica (02616) increasing by 12.87% and Akeso (01167) rising by 10.04% [4] - The Chinese Premier emphasized the need for high-quality technological support and policy backing for the biopharmaceutical industry, aiming to enhance innovation and production of effective medicines [4] Stablecoin Concept Stocks - Stablecoin-related stocks were active, with ZhongAn Online (06060) rising 6.98% and Yao Cai Securities (01428) increasing by 5.75% [4] - Goldman Sachs reported a new expansion cycle for the stablecoin market, potentially reaching trillions of dollars, with payment applications being a key growth driver [6] Notable Stock Movements - Crystal International (02232) reached a new high, closing up 12.66% at HKD 6.85, reporting a revenue of USD 1.229 billion, a 12.4% increase year-on-year [7] - Hong Kong Robotics (00370) surged 12.86% after signing a significant order for 10,000 humanoid robots, marking a milestone in the industry [8] - Huazhu Group (01179) reported a total revenue of RMB 6.426 billion for Q2 2025, a 4.52% increase, with a net profit of RMB 1.544 billion, up 44.7% [9] - Great Wall Motors (02333) saw a rise of 6.45% following the launch of its new PHEV model, which received over 21,856 orders within 24 hours [10] - ZTE Corporation (00763) increased by 5.38%, with analysts highlighting its underestimated progress in AI and network business [11]

Group 1 - The core viewpoint highlights a significant rise in Hong Kong pharmaceutical stocks following positive earnings reports, with Ping An Good Doctor increasing by 15.06% and Hengrui Medicine rising over 1% [1] - Ping An Good Doctor reported a revenue of 2.5 billion yuan for the first half of 2025, marking a year-on-year growth of 19.5%, exceeding market expectations [1] - Hengrui Medicine's half-year report showed a revenue of 15.761 billion yuan, a year-on-year increase of 15.88%, and a net profit attributable to shareholders of 4.45 billion yuan, up 29.67% [1] Group 2 - Two leading companies in the innovative drug sector, Hengrui and China National Pharmaceutical Group, are actively increasing their shareholdings, signaling positive market sentiment [2] - Hengrui plans to repurchase A-shares using its own funds, with a total investment of no less than 1 billion yuan and not exceeding 2 billion yuan, at a price not exceeding 90.85 yuan per share [2] - The Hong Kong pharmaceutical ETF (159718.SZ) is noted for its balanced composition, including innovative drugs, CXO, internet healthcare, and innovative medical devices, making it a convenient investment tool for the sector [2]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 12.00 [1][5]. Core Views - The company reported a revenue of HKD 6.1 billion in 1H25, reflecting a 1% year-over-year increase, and a 25% decrease in net profit to HKD 1.17 billion [1]. - The revenue from innovative and barrier products increased to 51% in 1H25, up from 36.1% in 1H24, indicating a positive trend in product performance [1]. - The nuclear medicine segment showed significant growth, with revenue reaching HKD 422 million, a 105.5% year-over-year increase, driven by the rapid uptake of Y90 microspheres [3]. - The company expects stable operational profit in 2H25 due to a low base effect and continued growth in the pharmaceutical technology and nuclear medicine sectors [1][2]. Summary by Sections Pharmaceutical Technology - The pharmaceutical technology segment achieved revenue of HKD 3.84 billion in 1H25, a 2.9% year-over-year increase, with respiratory and critical care products growing by 9.9% [2]. - The company anticipates stabilization in revenue for 2025, driven by unique product advantages and the gradual clearing of procurement impacts [2]. Nuclear Medicine - The nuclear medicine segment's revenue surged to HKD 422 million in 1H25, primarily due to the rapid market penetration of Y90 microspheres [3]. - The company has a robust pipeline with 27 nuclear medicine projects, focusing on integrated tumor diagnosis and treatment [3]. R&D Pipeline - The STC3141 project is expected to progress to Phase III trials within the year, with promising data from Phase II trials [4]. - The company is also looking to enhance its product portfolio through potential business development opportunities [4]. Profit Forecast and Valuation - The company forecasts net profits of HKD 2.1 billion, HKD 2.4 billion, and HKD 2.6 billion for 2025, 2026, and 2027 respectively [5]. - The target price of HKD 12.00 is based on a 20x PE ratio for 2025, aligning with comparable companies in the Hong Kong market [5].

Core Viewpoint - The innovative drug sector is experiencing a rebound, with the Hong Kong Stock Connect Innovative Drug ETF (520880) showing a positive performance after a brief decline, indicating renewed investor interest in the sector [1][3]. Company Performance - LIZHU Pharmaceutical reported a mid-year revenue of approximately 6.272 billion yuan, a slight decrease of 0.17% year-on-year, while net profit attributable to shareholders increased by 9.4% to about 1.281 billion yuan [2]. - The company has 39 products in the research pipeline, with 13 in the registration phase, 4 in Phase III clinical trials, 2 in process validation/BE phase, and 4 in Phase II clinical trials [2]. Industry Trends - High-level leaders emphasized the need for increased high-quality technological supply and policy support for the biopharmaceutical industry, aiming to enhance the quality and efficiency of drug development [3]. - CICC expressed optimism about the long-term development trend of innovative drugs, highlighting the advantages of domestic engineers, abundant clinical resources, and supportive policies [3]. - The innovative drug sector is transitioning from a follower to a leader in innovation, with domestic products expected to significantly participate in the global market over the next decade [3]. ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on the innovative drug industry chain [3]. - The index has shown a remarkable year-to-date increase of 101.58%, outperforming the Hang Seng Index and the Hang Seng Tech Index by 78.08 and 79.53 percentage points, respectively [6][7].

Core Viewpoint - The innovative drug sector is experiencing a rebound, with the Hong Kong Stock Connect Innovative Drug ETF (520880) showing a price increase of 1.36% on August 21, following two days of decline, indicating a positive market sentiment towards innovative pharmaceuticals [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) recorded a trading volume of 2.78 billion yuan, reflecting strong investor interest [1]. - Key stocks in the innovative drug sector, such as King’s Ray Biotechnology and Lepu Biopharma, saw price increases of over 6%, while others like Livzon Pharmaceutical and Crystal Technology rose by more than 5% [1][2]. Group 2: Company Performance - Livzon Pharmaceutical reported a revenue of approximately 6.272 billion yuan for the first half of the year, a slight decrease of 0.17% year-on-year, but net profit increased by 9.4% to about 1.281 billion yuan [2]. - The company has 39 products in the research pipeline, with 13 in the registration phase and 4 in Phase III clinical trials, indicating a robust development strategy [2]. Group 3: Policy and Industry Outlook - Recent government initiatives emphasize enhancing high-quality technological supply and policy support for the biopharmaceutical industry, aiming to boost innovation and production of effective new drugs [3]. - China International Capital Corporation (CICC) expresses optimism about the long-term development of the innovative drug industry, highlighting the advantages of domestic engineering talent, rich clinical resources, and supportive policies [3]. - The innovative drug sector is transitioning into a 2.0 era, with expectations for significant participation in the global market over the next decade, supported by improved cash flow and R&D cycles [3]. Group 4: Index Performance - The Hang Seng Stock Connect Innovative Drug Select Index has seen a cumulative increase of 101.58% year-to-date as of July 31, significantly outperforming other indices [6]. - The index has shown exceptional performance compared to the Hang Seng Index and the Hang Seng Technology Index, exceeding their returns by 78.08 and 79.53 percentage points, respectively [6].

Core Viewpoint - The Hong Kong stock market shows mixed performance, with the Hong Kong Stock Connect Innovative Drug ETF (159570) rebounding after two days of decline, indicating strong investor interest and significant capital inflow [1][8]. Group 1: ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) experienced a nearly 1% increase, with trading volume surpassing 1.1 billion HKD, and a net inflow of 32 million HKD on the day, marking 23 consecutive days of net inflow, totaling over 1 billion HKD in the last 20 days [1]. - As of August 19, the latest scale of the Hong Kong Stock Connect Innovative Drug ETF (159570) exceeded 16.5 billion HKD, leading in both scale and liquidity [1]. Group 2: Stock Performance - Most constituent stocks of the Hong Kong Stock Connect Innovative Drug ETF (159570) showed positive performance, with notable increases including Rongchang Bio up over 4%, and several others like Yuanda Pharmaceutical and King’s Ray BioTech up over 3% [3]. - A detailed performance table shows various stocks with their respective changes, highlighting the mixed performance across the sector [4]. Group 3: Company Financials - H Company reported a significant increase in its financial performance for the first half of 2025, achieving a revenue of 15.76 billion CNY, a year-on-year growth of 15.88%, and a net profit of 4.45 billion CNY, up 29.67% [4][6]. - The company’s operating cash flow reached 4.3 billion CNY, reflecting a 41.80% increase, with R&D investment totaling 3.87 billion CNY, of which 3.23 billion CNY was capitalized [6][7]. Group 4: Market Outlook - The outlook for the Hong Kong stock market remains optimistic, with improving profitability in the innovative drug sector and a high earnings forecast rate, suggesting a potential lead over A-shares in the upcoming market cycle [8]. - The introduction of a new initial review directory for innovative drugs by the National Healthcare Security Administration is expected to provide additional growth opportunities, with 121 out of 141 drug names passing the initial review [9]. Group 5: Upcoming Events - The 2025 World Lung Cancer Conference (WCLC) is scheduled for September 6-9 in Barcelona, which will showcase significant research outcomes from domestic innovative drugs [5][9].

Group 1 - Recent industry capital buybacks demonstrate confidence in industry development, with Heng Rui announcing a plan to repurchase A-shares worth 1 to 2 billion yuan for employee stock ownership plans [1] - The performance assessment indicators for the company include innovative drug sales revenue, the number of new molecular entity IND approvals, and the number of innovative drug NDA applications accepted, with unlocking ratios set at 100%, 90%, and 0% [1] - The Vice President of China Biopharmaceutical repurchased 1 million shares, reflecting confidence in the company's development [1] Group 2 - Continuous policy support for the healthy development of the industry is highlighted, with a key leader emphasizing the need for high-quality technological supply and policy support to enhance the biopharmaceutical industry's quality and innovation [1] - On August 11, the Hang Seng Hong Kong Stock Connect Innovative Drug Index was officially adjusted to exclude CXO, becoming a "pure" innovative drug index, which more accurately reflects the overall performance of China's innovative pharmaceutical companies [1] - Historical performance of the index is expected to improve significantly after the exclusion of CXO, with the Hang Seng Innovative Drug ETF (159316) being the only ETF product tracking this index [1]

Market Performance - The Hang Seng Index closed at 25,165, up 0.17% for the day and up 25.45% year-to-date [1] - The Hang Seng Tech Index closed at 5,541, down 0.01% for the day and up 24.02% year-to-date [1] - The Shanghai Composite Index closed at 3,766, up 1.04% for the day and up 12.37% year-to-date [1] Currency and Commodity Trends - The Renminbi Index is at 96.170, up 0.60% month-on-month but down 3.89% over six months [2] - Brent crude oil is priced at $66.590 per barrel, down 2.68% month-on-month and down 9.88% over six months [2] - Gold is priced at $3,326.19 per ounce, down 2.06% month-on-month but up 13.20% over six months [2] Company Highlights - Pop Mart's founder Wang Ning stated that the company expects to achieve revenue of 30 billion RMB this year, significantly higher than the previous year's 10 billion RMB [10] - WuXi Biologics reported a 16.1% increase in revenue for the first half of the year, reaching 9.953 billion RMB, driven by expanded service offerings and increased utilization of existing and new capacities [12] - China Biologic Products received breakthrough therapy designation for its selective HER2 TKI, indicating significant progress in its drug development pipeline [13] Notable Market Events - Tencent's WeChat Work has integrated AI capabilities and has connected over 14 million enterprises, indicating strong growth in enterprise communication solutions [11] - The UK reported a year-on-year CPI increase of 3.8% in July, the highest in a year and a half, which may impact market expectations for interest rate adjustments [14][15] - The U.S. Commerce Secretary indicated that Intel must exchange equity for government subsidies, which could set a precedent for other companies like TSMC and Samsung [16] IPO and New Listings - Recent IPOs include Tianyue Advanced and Yinnuo Pharmaceutical, with significant oversubscription rates indicating strong investor interest [25] - Upcoming IPOs include Shuangdeng Co. and Jiaxin International Resources, with expected listing dates in late August [25][26]

8月21日早盘，创新药概念集体高开，恒瑞医药绩后涨超1%;，港股医药ETF (159718.SZ)现涨0.66%。成 分股平安好医生(01833)上涨7.69%，丽珠医药(01513)上涨5.95%，金斯瑞生物科技(01548)上涨4.62%， 中国生物制药(01177)，科伦博泰生物-B(06990)等个股跟涨。 港股医药ETF板块构成均衡，不仅包含创新药，还涵盖CXO、互联网医疗、创新器械等港股特色标的， 是投资者配置港股医药板块的便捷标准化工具。建议关注港股医药ETF(159718.SZ)及其联接基金(A 类:019598,C类:019599)。 消息面上，恒瑞医药发布半年报，25H1营业收入157.61亿元,同比增长15.88%；归母净利润44.5亿元， 同比增长29.67%；第二季度营业收入85.56亿元，同比增长12.53%；归母净利润25.76亿元，同比增长 24.88%。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 值得注意的是，恒瑞拟以自有资金，采用集中竞价交易方式从二级市场回购A股股份，用于A股员工持 股计划。拟使用资金总额不低于人民币10亿元，不超过人民币20 ...